New drugs for hyperlipidemia

With introduction of Statins and its huge randomised clinical trials, it is considered as first line therapyAgainst Dyslipidemia Atherosclerotic disease. But other group of patients with Familial Hypercholesterolemia, Hyper lipoproteinemia, Hypertriglyceridemia, and patients with Reduced HDL-COr those with intolerance or poor response to statins need new treatments for their condition.60-80% of patients have residual cardiovascular risk with optimal statin treatment regarding above conditions.Now, new classes of Anti Lipid medications have developed and some of them are available for clinical use.The Pro-Protein Convertase Subtilisin / Kexin Type 9 inhibitors, increase expression of LDL receptors in hepatocytes, by increasing receptor recycling. They are potent anti LDL-C and reduce 60-70% of LDL-CIn patients with familial Hypercholesterolemia.Anti-Sense Oligo Nucleotide against Apolipoprotein B (Apo-B) ,and Microsomal Triglyceride Transport Protein (MTP) Inhibitors , reduce Apo-B by blocking hepatic synthesis of very low density lipoproteins (VLDL) pathway. Apolipoprotein A1 (APO-A1) mimetic, with beneficial effect of increasing HDL-C is considered to regress atherosclerotic plaques and reduce LDL-C levels.The new treatments are promising in different RCT’S and new trials are underway to answer safety and long term results in reducing cardiovascular mortality.